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Summary
Osteoporosis is a common complication of chronic kidney
disease (CKD), and the latter is a major risk factor for cardio-
vascular mortality. Recent studies have elucidated some of
the mechanisms by which CKD is a cardiovascular risk, and
they relate to osteoporosis. Thus, the mechanisms of CKD
induced cardiovascular risk provide valuable insight into the
relationship between cardiovascular disease and osteoporo-
sis, and they are reviewed here. Observational studies have
determined hyperphosphatemia to be a cardiovascular risk
factor in chronic kidney disease. Mechanistic studies have
elucidated that hyperphosphatemia is a direct stimulus to
vascular calcification, which is one cause of morbid cardio-
vascular events contributing to the excess mortality of
chronic kidney disease. Hyperphosphatemia in chronic kid-
ney is due to failure of excretion by the kidneys and excess
bone resorption. It stimulates vascular cells to mineralize
atherosclerotic plaques through osteoblastic processes. Hy-
perphosphatemia in chronic kidney disease is a distinct syn-
drome characterized by disordered skeletal remodeling, het-
erotopic mineralization and cardiovascular morbidity. The
heterotopic mineralization stimulated by CKD is relevant to
osteoporosis.
KEY WORDS: phosphorus, cardiovascular disease, osteoporosis, kidney
disease, osteoblasts.
Introduction
In chronic kidney disease (CKD), hyperphosphatemia is asso-
ciated with significant pathophysiology. This pathophysiology
contributes to the high rates of mortality observed in CKD (1).
Approximately 11-15% of Americans have CKD (2-4), and their
risk of death due to a cardiovascular event related cause is
higher than their risk of surviving and needing renal replace-
ment therapy for end stage kidney disease (ESKD) (1, 2, 4).
The mortality rates of patients surviving CKD and receiving he-
modialysis are extremely high such that a 30 year old patient
with ESKD has a life expectancy similar to a ninety year old
with normal renal function (2). The mechanisms of this excess
risk of cardiovascular disease are not completely understood.
The well characterized risks of cardiovascular disease in the
general population do not explain the increased risk in CKD (1,
3). Observational studies suggest that the well known propen-
sity of ESKD patients to develop heterotopic mineralization of
soft tissues including the vasculature is an important compo-
nent of the cardiovascular risks of ESKD (5, 6). Furthermore,
several observational studies demonstrate that hyperphos-
phatemia is an independent cardiovascular risk factor in CKD
(7-9). Hyperphosphatemia has been linked to vascular calcifi-
cation (10-12). 
Pathogenesis of hyperphosphatemia in CKD 
Kidney injury impairs the ability of mammals to maintain phos-
phorus balance, and in human chronic kidney disease, phos-
phorus homeostasis is lost and positive phosphate balance oc-
curs in the later stages (4 and 5) of kidney diseases (13, 14).
Loss of phosphorus homeostasis due to excretion failure in
chronic kidney disease results in hyperphosphatemia (15, 16)
due to positive balance increasing the concentration in the ex-
changeable phosphorus pool, often when the pool size is re-
duced as in the adynamic bone disorder (Fig. 1). Surprisingly
and not generally adequately considered, the skeleton con-
tributes to hyperphosphatemia in CKD and ESKD through the
effects of disordered bone remodeling. There are multiple
skeletal remodeling disorders discussed below in CKD, but all
of them are associated with excess bone resorption compared
to bone formation. Thereby, they contribute to hyperphos-
phatemia and effectively block the skeleton from exerting its
normal reservoir function when positive phosphate balance oc-
curs. 
The normal function of the skeleton as a reservoir when
phosphate balance is positive is seen in several syndromes
of hyperphosphatemia in mammalian pathophysiology. All of
them except immobilization and chronic kidney disease are
associated with increased skeletal mass and mineralization
due to phosphorus deposition into the skeletal storage reser-
voir. In chronic kidney disease, there is a complex set of loss-
es and adaptations in skeletal function that produce bone dis-
orders that complicate the state (see section on “Renal os-
teodystrophy”). Recent discoveries characterize all forms of
skeletal function disorder in chronic kidney disease as having
excess bone resorption rates compared to bone formation
rates (see section on “Osteoporosis in chronic kidney dis-
ease”). Therefore, the skeleton is contributing to hyperphos-
phatemia in chronic kidney disease, and the reservoir func-
tion of the skeleton that is supposed to act in the presence of
positive phosphorus balance is blocked. The outcome of this
change in physiology to a new pathophysiology requires that
a new phosphate reservoir for the positive balance is estab-
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lished. This new reservoir is soft tissue organs including the
vasculature (Fig. 1). The problem with establishing the new
reservoirs of phosphate storage is that they produce disease. 
One of the new reservoirs for phosphate deposition estab-
lished when excretion is no longer sufficient to maintain bal-
ance, the vasculature (Fig. 1), is especially disease causing.
Vascular calcification in CKD is not well tolerated as it pro-
duces blood vessel stiffness. There are two forms of vascular
calcification prominent in CKD, calcification of atherosclerotic
neointimal plaques and arterial medial calcification. CKD
markedly stimulates both forms. The atherosclerotic calcifica-
tion is especially appreciated in the coronary arteries as it is
measured by the increasingly popular imaging techniques for
determining coronary artery calcification (17, 18). However,
arterial medial calcification is as clinically important, as it is the
likely the most important factor in vascular stiffness and in-
creased pulse pressure in CKD. The vascular calcification so
prominent in CKD is not specific to CKD as it is seen in type 2
osteoporosis of elderly subjects and in patients with diabetes.
Thus, the discovery of pathogenetic mechanisms of vascular
calcification in CKD most likely has relevance to osteoporosis
and diabetes as well. 
Methods, Results, and Discussion
In order to study the mechanisms of CKD stimulated vascular
calcification, we developed a translational animal model. We
started with a model of atherosclerosis that develops cardiac
valvular and atherosclerotic neointimal plaque calcification, the
low density lipoprotein receptor deficient mouse (LDLR-/-) fed a
high fat diet. To the model we added ablation induced kidney
failure, and demonstrated marked stimulation of aortic athero-
sclerotic calcification (19). We discovered that bone morpho-
genetic protein-7 (BMP-7) prevented the development of CKD
stimulated vascular calcification (19). Furthermore, the high fat
fed CKD mice exhibited hyperphosphatemia that was corrected
by BMP-7 (20). In investigating the mechanism of hyperphos-
phatemia correction by BMP-7 we found that bone formation
was stimulated correcting the adynamic bone disorder that
complicates the kidney failure in these mice (20) (Fig. 2). Renal
phosphate excretion was not increased, and we questioned
how much of the BMP-7 effect on vascular calcification was
due to bone formation induced correction of hyperphos-
phatemia. To examine this, we added phosphate binders to the
high fat diet in an attempt to isolate hyperphosphatemia correc-
tion as a single entity separate from the other actions of BMP-7.
To our surprise, phosphate binders were very effective in pre-
venting vascular calcification. We first used CaCO3 (20), but sub-
sequently have studied sevelamer carbonate (21) and LaCO3
with similar results. 
The LDLR-/- high fat fed mouse is characterized by obesity, hy-
pertension and insulin resistance that progresses to diabetes
and severe hypercholesterolemia. Thus, the mouse model is
relevant to the human metabolic syndrome, and the develop-
ment of kidney disease in obese diabetics. Even the renal os-
teodystrophy complicating CKD, the adynamic bone disorder,
is the same as observed in patients with diabetic nephropathy.
The vascular calcification of the model was discovered by
Towler and Semenkovich (22). They found that osteoblastic
transcriptional activity was present in the aorta, and their model
is the starting point to which we add CKD. At the beginning, in
other words our high fat fed sham operated animals, expressed
BMP-2, BMP-4, Runx2, Msx2, osteocalcin and osteopontin in
the vasculature, especially the aorta. This is relevant because
several investigators have demonstrated that the vasculature
of patients with CKD/ESKD expresses osteoblastic markers
(23-26). However, our high fat fed sham operated animals had
a low level of vascular calcification that was stimulated two to
four fold by the induction of CKD (19).
To further investigate mechanisms of atherosclerotic calcifi-
cation, we developed an in vitro model to study in cell culture
with the strategy of confirming discoveries made in vitro using
our animal model. We began by obtaining primary cultures of
human vascular smooth muscle cells (hVSMC) from areas of
aortic atherosclerotic plaques, which were expanded and
then exposed to an increase in media phosphorus concentra-
tions (Fig. 3). We demonstrated that the starting tissue and
the primary cultures in regular media expressed BMP-2,
BMP-4, Runx2, Msx2, osteocalcin and osteopontin. Thus, it
appeared that BMP-2 and 4 as bone morphogens were stimu-
lating an osteoblastic differentiation program in vascular cells
directed by the osteoblast specific transcription factors. This
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Figure 1 - Phosphorus homeostasis is lost in chronic kidney disease
due to failure of excretion. Despite reductions in the fraction of filtered
phosphorus that is reabsorbed, eventually the filtered load becomes in-
sufficient to maintain homeostasis, and positive phosphorus balance
ensues. Kidney disease decreases the exchangeable phosphorus pool
size by inhibiting bone formation. The skeletal mineralization fronts at
the sites of new bone formation are significant components of the ex-
changeable phosphorus pool. Positive phosphate balance is associated
with establishment of heterotopic mineralization sites in soft tissue or-
gans and the vasculature. Exit from the exchangeable phosphorus pool
into the vasculature is portrayed as a bidirectional process because we
have been able to demonstrate that stopping the exit into the vascula-
ture results in diminishment of established vascular calcification levels.
Figure 2 - Treatment of CKD in LDLR-/- high fat fed mice corrects the
adynamic bone disorder (ABD). BMP-7, 10 mcg/kg injected IP weekly
increased osteoblast number and surfaces on metaphyseal trabeculae.
The increase in bone formation rate restored the reduced bone volume
to normal over the course of treatment.
Phosphorus balance is lost in CKD
Osteoblasts on metaphyseal trabecular
bone surfaces of LDLR-/- high fat fed mice
CKD CKD plus BMP-7
Absorption
750 mg/day
Blood
Phosphorus 
pool
Excrete urine
650 mg/day
CV
200
100Secretion
150 mg/day
Formation
100 mg/day
Resorption
150 mg/day
FOOD
1000 mg/day
1150 mg/day
Excrete feces
300 mg/day
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data is in agreement with other investigators (27), including
those who reported increased levels of BMP-2 and 4 in ather-
osclerotic lesions (28, 29). However, the primary hVSMC cul-
tures did not mineralize the extracellular matrix as osteoblast
cultures do (30). When media phosphorus was increased by
1 or 2 mM to 2 or 3 mM (equal to a serum phosphorus of 6 to
9 mg/dl), heavy matrix mineralization ensued (Fig. 3). Analy-
sis of the osteoblastic transcription program revealed that the
very low levels of osterix expression in the starting cultures
were increased several fold by the increase in media phos-
phorus. Blocking the increase in osterix expression in high
phosphate media prevented matrix mineralization (31). Both
our translational model in vivo and our cell culture model in
vivo represent mineralization due to the atherosclerotic
process. We observe mainly neointimal calcification in vivo,
and the medial calcification we observe is in proximity to ath-
erosclerotic plaques.
When we examined our high fat fed LDLR-/- aortas from the
various groups of animals, we found that the sham operated
high fat fed animals had low or undetectable levels of osterix
expression that were increased several fold when CKD was in-
duced (31). Most importantly, treatment of CKD high fat fed hy-
perphosphatemic animals with phosphate binders inhibited os-
terix expression (31). As expected without a critical osteoblas-
tic transcription factor, matrix mineralization (neointimal calcifi-
cation) was severely compromised. 
The mechanism of phosphorus stimulation of matrix mineral-
ization in vitro has been studied by Jono et al. (32) and Li et al.
(33) in VSMC and by Beck et al. in osteoblastic cells (34, 35).
These authors have demonstrated that the effect of media
phosphorus was through activation of ERK1/2, and it was
blocked by inhibition of sodium dependent phosphate transport
proteins. Studies with RNAi to Pit-1 (33, 36) indicate that block-
ing the actions of high phosphorus culture media in vitro are
similar to the effects of lowering the serum phosphorus in vivo,
that of inhibiting osteoblastic stimulation of matrix mineraliza-
tion. 
Thus, phosphorus is more than a stimulator of vascular calcifi-
cation acting through an elevated calcium-phosphorus product
in CKD and ESKD. It is a signaling molecule serving to com-
plete osteoblastic differentiation in the aorta, and an important
component of the action of CKD to stimulate atherosclerotic
calcification. The results of the translational animal studies
and the studies in vitro just discussed are in agreement with a
new clinical consensus that has lead to renaming of renal os-
teodystrophy by the KDIGO Foundation as the chronic kidney
disease mineral bone disorder (CKD-MBD) in recognition of
the roles of the skeleton in hyperphosphatemia and vascular
calcification (37).
Renal osteodystrophy in the CKD-MBD
There are several disorders of bone remodeling that compli-
cate CKD and ESKD and represent the skeletal component of
the CKD-MBD. For purposes of this discussion, consideration
will be limited to the most prevalent forms, a high turnover
disorder, osteitis fibrosa, and a low turnover disorder, the
adynamic bone disorder. Elevated remodeling rates associat-
ed with secondary hyperparathyroidism, produce an os-
teoblast phenotype in CKD that has reduced secretion of type
1 collagen and increased production of RANK ligand (RAN-
KL), the critical osteoclast differentiation factor. This results in
bone resorption outpacing bone formation. In addition, the
high remodeling rates are characterized by insufficient re-
placement of newly formed atypical “woven” bone with bone
formed on collagen lamellae. Thus, even with normal bone
mass, skeletal frailty may be problematic in the high turnover
osteodystrophy powered by secondary hyperparathyroidism
in CKD/ESKD. Finally, the excess in bone resorption may
lead to osteopenia and osteoporosis complicating CKD and
especially ESKD.
A second skeletal remodeling disorder has become increasing-
ly prevalent with administration of high doses of vitamin D
analogs in CKD/ESKD, the adynamic bone disorder (ABD) (38-
40). The ABD was originally thought to be due to suppression
of osteoblast function with high doses of vitamin D analogs (38,
40). The finding that vitamin D analogs stimulate, not inhibit,
bone formation and osteoblast function has put this contention
to rest (41-43). What is likely the case is that the negative ef-
fects of CKD on skeletal anabolism are uncovered by suppres-
sion of PTH. This demonstrates that higher than normal PTH
levels are required to maintain bone remodeling in CKD (44). In
the ABD the profound suppression of osteoblast function (Fig.
2) is not matched by equal suppression of osteoclast function.
As a result, excess bone resorption is observed that may lead
to osteopenia and osteoporosis. 
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Figure 3 - Schematic of the experimental plan for in vitro studies
demonstrating that high phosphorus causes vascular calcification and
osteoblastic gene expression. Human vascular smooth muscle cells
(hVSMC) derived from atherosclerotic aortas expressed increased lev-
els of morphogens, specific transcription factors and biomarkers of the
osteoblast and decreased levels of those corresponding to contractile
hVSMC. Yet the cells did not mineralize until media Pi was increased
from 1 to 2 mM. High media Pi stimulated osterix expression, and when
osterix expression was diminished in the presence of high media Pi
there was no mineralization (31).
Table I - Hyperphosphatemic syndromes
Increased intake
Transcellular shifts from intracellular to extracellular spaces
Excess bone resorption
Decreased renal excretion
Idiopathic hyperparathyroidism
Pseudohypoparathyroidism
FGF-23 deficiency
Tumoral calcinosis
Chronic kidney disease
Acromegaly
Artifactual
VSMC from atherosclerotic aortas as a model 
of atherosclerotic calcification in vitro
Atherosclerotic aorta
2-3 weeks, culture expansion
Absence of mineralization
Culture isolated cells
Cell Matrix Mineralization
Smooth muscle cells isolatedCells express BMP-2/4
RUNX2, MSX2, osteocalcin,
alkaline phosphatase
and osteopontin.
Media Pi, 1 mM
Cells express osterix
and extensively mineralize
the matrix
(Blocking osterix expression blocked mineralization)
2-3 weeks
Treat with media containing 2 mM Pi
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Osteoporosis in chronic kidney disease
The balance between bone formation and resorption may be
either negative or positive in CKD. When positive, osteosclero-
sis results, but this is rare in modern medicine. In the case of
negative bone balance, bone loss occurs in cortical and can-
cellous bone and is more rapid when bone turnover is high. In
those cases, bone densitometry will detect osteopenia or os-
teoporosis. The prevalence of osteoporosis in the population
with CKD exceeds the prevalence in the general population
(45-47). Osteoporosis is observed in CKD before dialysis is re-
quired for end stage kidney failure (48). When bone turnover is
high, as in secondary hyperparathyroidism with osteitis fibrosa,
bone resorption rates are in excess of bone formation and os-
teopenia progressing to osteoporosis may result. When bone
turnover is low, as in the ABD, although both bone formation
rates and bone resorption are reduced, resorption is in excess
and loss of bone mass occurs. Thus, osteoporosis may be ob-
served with either high turnover (48-51) or low turnover (52)
forms of osteodystrophy. When bone resorption exceeds bone
formation rates in CKD, phosphorus and calcium release con-
tribute to hyperphosphatemia and hypercalcemia. The increase
in skeletal mineral deposition that should result from hyper-
phosphatemia or hypercalcemia is blocked, and heterotopic
mineralization is stimulated, especially in the vasculature. The
failure of the skeleton to absorb positive phosphate balance in
CKD is an important stimulus to heterotopic mineralization, and
links the skeleton and osteoporosis in CKD to cardiovascular
events and mortality. This link between osteoporosis and vas-
cular calcification, now partly defined in CKD, is not specific to
CKD. Type 2 osteoporosis is strongly associated with vascular
calcification, and perhaps, the mechanisms defined in CKD re-
lated to the serum phosphorus as a signal and positive phos-
phate balance also apply. 
The discussion of osteoporosis in CKD above is focused on os-
teoporosis caused by CKD itself. However, many patients with
CKD have osteoporosis independent of CKD. These patients
may be elderly or may have post-menopausal osteoporosis. In
addition, it is clear that gonadal hormone deficiency, as in post-
menopausal osteoporosis, is also caused by CKD and is an-
other factor in the pathogenesis of osteoporosis in CKD. Thus,
osteoporosis in CKD presents a difficult differential diagnosis
between the type 2 osteoporosis of aging, gonadal hormone
deficiency, and excess bone resorption associated with the
CDK-BMD.
In conclusion, hyperphosphatemia in CKD is a distinct syn-
drome. It represents one component of the increased risk of
cardiovascular disease in CKD that has been successfully ana-
lyzed. Hyperphosphatemia in CKD represents a signal that het-
erotopic sites of mineralization are being used to compensate
for the failure of reservoir function of the skeleton in positive
phosphate balance. In fact, hyperphosphatemia itself is one of
the signals activating heterotopic deposition sites, and func-
tions as a signaling molecule in stimulating atherosclerotic
neointimal mineralization that is markedly increased in CKD.
The features of hyperphosphatemia in CKD, especially the fail-
ure of the skeletal reservoir function, may not be unique to
CKD and heterotopic mineralization including the vasculature,
in type 2 osteoporosis and diabetes appear to be linked to a
similar pathogenesis. This requires additional study but may re-
late to the severe cardiovascular disease leading to morbid
cardiac events in these conditions similar to CKD. 
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